A groundbreaking research study published in the Mayo Clinic Proceedings suggests that combination therapy of statins and ezetimibe may transform cardiac care by significantly reducing cardiovascular risks and mortality rates.
Led by Maciej Banach, MD, PhD from Poland and leader of the International Lipid Expert Panel (ILEP), the study analyzed 14 studies involving over 108,000 high-risk individuals. The results revealed that the combination therapy resulted in a mean reduction difference of -12.96 mg/dL in LDL cholesterol levels and significantly diminished the risk of all-cause mortality by 19%, major adverse cardiovascular events by 18%, and stroke incidence by 17%.
The study’s findings support the integration of combination therapy early in treatment protocols, particularly for high and very high-risk groups. Dr. Carl J. “Chip” Lavie, Jr., MD, a co-author of the study, emphasized the importance of proactive, combination-based strategy in lipid-lowering therapy.
According to Dr. Lavie, optimizing LDL-C reductions early can dramatically improve patient outcomes and reduce the global burden of cardiovascular disease. The study authors encourage clinicians to adopt a framework that includes upfront combination therapy for very high-risk patients, even before they suffer a cardiac event or stroke.
Source: https://medicaldialogues.in/cardiology-ctvs/news/upfront-combination-therapy-of-statin-and-ezitamide-may-transform-cardiac-care-suggests-research-146190